Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	5.73T
Revenue (ttm)	1.47T
Net Income (ttm)	116.48B
Shares Out	12.68M
EPS (ttm)	9,186.55
PE Ratio	49.20
Forward PE	33.64
Dividend	1,250.00 (0.28%)
Ex-Dividend Date	n/a

Volume	52,069
Average Volume	89,446
Open	453,000
Previous Close	451,000
Day's Range	445,500 - 457,500
52-Week Range	214,500 - 494,000
Beta	0.48
RSI	58.47
Earnings Date	Feb 13, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.